Compare AbCellera Biologics Inc (ABCL) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Las Vegas Sands Corp. — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Las Vegas Sands Corp. trades at $46.14 (market cap $30.52B). The key difference: Las Vegas Sands Corp. is far larger — about 13× AbCellera Biologics Inc's market cap, and Las Vegas Sands Corp. pays a 2.39% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LVS | |
|---|---|---|
Market Cap | $2.35B | $30.52B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $69.49 |
52-Week Low | $2.78 | $46.06 |
Enterprise Value | $1.99B | $42.92B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
LVS trades at $46.06, down 1.98% on the day, amid a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations, and maintains robust profitability with a net income margin of 13.41%. Recent news highlights ESG achievements and Macao's economic diversification efforts. Cash flow trends show positive net cash flow in 2025 after previous years of outflows.
The outlook for LVS is supported by solid fundamentals and analyst optimism, with a consensus price target of $66.38 implying significant upside. Risks include high debt levels, with a debt-to-asset ratio of 73.15% in 2025, and exposure to Macao's regulatory environment. Institutional sentiment remains positive, with no sell ratings among 49 analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
